Should I buy STAAR Surgical Company (STAA) stock or is it too late?
⭐ The most reliable of them, either direction: UBS — 58% of its targets hit on this sector (74 calls tested). It aims for $19 (-15 %), call made on August 14, 2026, maturing on August 14, 2027 (14 d ago).
Firm-by-firm track record on STAAR Surgical Company
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Canaccord Genuity | 44 % | +33.4 % | 16 | $32 +43% |
| Stephens & Co. | 29 % | +18.0 % | 7 | $17 -24% |
| BTIG | 20 % | -15.5 % | 5 | $53 +137% |
| Mizuho | 0 % | -42.9 % | 6 | $27 +21% |
| Needham | 0 % | -31.0 % | 9 | — |
✅ Reasons to believe
- Median price target $28, i.e. +25% from the current price ($22).
⚠️ Reasons to hesitate
- Even the most reliable firm on STAA, Jefferies (50% hit rate, 2 scored calls), only targets $22 (call made on January 28, 2026, maturing on January 28, 2027) (-4%) in its most recent call. The stock may already have run past its target.
- The consensus is not unanimous: of 7 ratings, 4 are neutral and 1 is a sell.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- No dividend: your return depends only on price appreciation.
The analyst consensus on STAA
Median target $28 (+25%) · 7 ratings · Hold consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in STAAR Surgical Company now?
We won't decide for you. The facts: 29% of analysts rate it a buy, median target $28 (+25%), and Jefferies (most reliable on STAA, 50%) targets $22. Weigh that against valuation. This is not personalized advice.
Is it too late to invest in STAAR Surgical Company?
Not according to analysts: the median target ($28) is still +25% above the current price ($22) (most reliable on STAA: Jefferies, 50%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is STAAR Surgical Company still worth investing in?
It depends on the gap between the price ($22) and its estimated value: analysts target $28 on median (+25%), with 29% buys (most reliable on STAA: Jefferies, 50%). Cross-check with their real reliability on STAA and the cautions above. Information, not advice.
What's the main risk in buying STAA?
Even the most reliable firm on STAA, Jefferies (50% hit rate, 2 scored calls), only targets $22 (call made on January 28, 2026, maturing on January 28, 2027) (-4%) in its most recent call. The stock may already have run past its target.
→ Go deeper: the full STAAR Surgical Company profile (consensus, analyst reliability, price target, performance).